Analyst Insights on Stocks: Fusion-IO, Orexigen, Corcept, SPS Commerce Feb. 21st
Fusion-IO, Inc.(NYSE:FIO): Caris said rumors that Intel (NASDAQ:INTC) may be interested in acquiring Fusion-io (NYSE:FIO) is “extremely unlikely.” The analyst continues to be cautious on Fusion-io and reiterates its Sell rating. Craig-Hallum said rumors that Intel (NASDAQ:INTC) may be interested in acquiring Fusion-io (NYSE:FIO) is “extremely unlikely.” The analyst continues to be cautious on Fusion-io and reiterates its Sell rating.
Orexigen Therapeutics, Inc.(NASDAQ:OREX): Leerink says Orexigen is becoming its top small-cap pick in biotech following its Global Healthcare Conference. The firm has increased confidence that the company’s obesity drug Contrave will reach the market by 2014 at the latest, and reiterates an Outperform rating on the stock with a $5 price target.
Corcept Therapeutics Inc.(NASDAQ:CORT): BioLogic Equity believes the label for Corcept Therapeutics’ just approved Korlym presents a major commercial challenge for the company and reiterates a Sell rating on the stock.
SPS Commerce, Inc.(NASDAQ:SPSC): Craig-Hallum said recent weakness in SPS Commerce since the quarter report is a buying opportunity and notes the company is a consistent grower and the network effect is just starting to take off. Shares are Buy rated.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.
To contact the reporter on this story: Derek Hoffman at firstname.lastname@example.org
To contact the editor responsible for this story: Damien Hoffman at email@example.com